Nature Communications

Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial

2026-06-15

Full text

DOI https://doi.org/10.1038/s41467-026-74483-1